SynthesisWorld journal of surgical oncology2026
Systematic review and meta-analysis comparing postoperative and oncological outcomes between local excision plus radiotherapy versus total mesorectal excision for rectal cancer.
Synthesis in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundTotal mesorectal excision (TME) is the standard treatment for middle to lower rectal cancer. However, it is associated with significant postoperative complications and functional impairments. Local excision (LE) combined with neoadjuvant radiotherapy (RT) has emerged as a less invasive alternative and has shown potential for organ preservation. This study aimed to compare the short-term and long-term outcomes of LE + RT versus TME in selected patients with rectal cancer. MATERIALS AND
methodsThis systematic review and meta-analysis were conducted following a comprehensive literature search of human studies published in English, completed by April 2025. Inclusion criteria consisted of rectal cancer up to cT3 disease and/or showed a favorable response to neoadjuvant therapy. Postoperative outcomes assessed included operative time, blood loss, morbidity, length of hospital stay, and permanent stoma rate. Oncological and survival outcomes were also evaluated.
resultsA total of six studies were included. They consisted of five randomized controlled trials and one prospective clinical trial, with a total of 679 patients. Of these, 366 were treated with LE + RT and 313 with TME. Pooled analysis showed that the LE + RT group was associated with a significantly shorter operative time, a lower overall morbidity, and a shorter postoperative hospital stay. No significant differences were observed between the groups in oncological or survival outcomes.
conclusionsThis study suggests that, in selected rectal cancer patients, LE + RT may represent a less invasive alternative with comparable oncological outcomes to TME. LE + RT may subsequently be a viable treatment option, especially in patients seeking organ preservation or in patients unfit for TME.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.